All News

#Multimorbidity in women with #rheumatoidarthritis is increased compared to men with RA. However, women and men without RA have similar levels of multimorbidity. Abs#1656 #ACR21 @RheumNow https://t.co/iXhXOldTy0 https://t.co/CsOM7odE69

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Ab#1658 - Autoimmune Risks in Relatives of RA pts. 1st degree relatives have risk of: ▶️ AI thyroid (OR 1.3) ▶️ Celiac (1.5) ▶️ SLE (1.3) ▶️ IBD - no ⬆️ risk ⭐️1st, 2nd, 3rd degree relativ: ⬆️ risk of RA ⭐️2nd degree: ⬆️ risk SLE https://t.co/ATHdemoF45 @Rheumnow #ACRbest https://t.co/JcuZmg9L8E

Links:

Eric Dein ericdeinmd ( View Tweet)
GLORIA RCT: 400+ pts. Low dose Pred in RA >65yo on top of other treatments 2yrs. Authors conclude benefit/risk balance in favour of GCs 🧐 2 thoughts: 1️⃣ CV risk linked to GCs ⬆️ over time and cumulative dose: Follow up= short! 2️⃣ Small # for CV events #ACR21 #Abst 1678 @RheumNow https://t.co/QECJR68ZJu
Aurelie Najm AurelieRheumo ( View Tweet)
Dr Deike on prevalence and incidence of PsA in Germany. Prevalence 5-6/1000. Incidence 30-40/100000. Marked age variations that don't really make sense for prevalence. Abstr#1785 #ACR21 @RheumNow https://t.co/uW0ruW2Jda
Richard Conway RichardPAConway ( View Tweet)
What is the likelihood of developing an #autoimmunedisease in first-degree relatives of pts with #RA? Genealogical & phenotypic data suggests lower threshold for screening for autoimmune thyroiditis, #coeliac & #SLE in FDRs. Abs#1658 #ACR21 @RheumNow https://t.co/PdSZ05elsf https://t.co/AkIXDkWCM8

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Ab#L02 - #COVID19 vax in rheumatic pts: ❌No ⬆️ in disease activity scores post-vaccination ❌No serious adverse event ▶️Vax response 88% in RA, 78% in SLE, 87% other rheum diseases after 2 shots vs 100% controls ⭐️RTX and MMF ⬇️ responses @Rheumnow https://t.co/BChhmW0jpy https://t.co/2q8IKRoYqW

Links:

Eric Dein ericdeinmd ( View Tweet)
Dr Hebing on s/c vs oral methotrexate. erythrocyte methotrexate polyglutamates significantly higher with s/c administration. s/c consistently seems to be the better option, better efficacy, less side effects. Abstr#1695 #ACR21 @RheumNow https://t.co/kLGr6pVnxQ
Richard Conway RichardPAConway ( View Tweet)
Can we predict which PsO pts will develop PsA? Machine learning and phenotyping of blood immune cell subsets identified an immune profile to discriminate PsO from PsA. Abs#1774 #ACR21 @RheumNow https://t.co/PERx86jjkJ https://t.co/oEpbMZ0nnK

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Congrats to Dr. Debaditya Roy, Dr. Chinenye Osuorji and Dr. Vaneet Sandhu on the leaderboard for engaged learning during #ACR21 @rheumnow My points are pathetic compared to theirs and the top 10 https://t.co/yYppc029DM
TheDaoIndex KDAO2011 ( View Tweet)
#ACR21 Ab#L03: B cell depletors and #COVID19 vax: ⭐️B cell count <40 around vax had lower response to vax, than 40+ B-cell, independent of RTX or BEL ▶️ Timing of vax around B cell return can improve response @Rheumnow https://t.co/1B7Bnb1QQu https://t.co/bKnfw6gD8O

Links:

Eric Dein ericdeinmd ( View Tweet)
#ACR21 #Abstr1491 What’s new in skin #lupus aetiology? Paired skin & blood using scRNA-seq: 💠Nonlesional skin in CLE/SLE is IFN-I-riched 💠Lupus-enriched CD16+ DCs undergo robust IFN education in the skin & gained pro-inflammatory phenotypes @RheumNow https://t.co/70zrC4T7SB https://t.co/75HjvGmNTa

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In this study by Prof MAringer et al, majority of #lupus pts enrolled in TULIP 1/2 met the the EULAR/ACR 2019 #SLE criteria 🦋Of few pts not meeting new criteria, most were ANA- w/detectable anti-dsDNA/Smith Ab Better outcomes for criteria+ in TULIP1/2? @RheumNow #ACR21 abs1733 https://t.co/XpfMZQLGUv
sheila RHEUMarampa ( View Tweet)
Dr Coras on "ITIS" anti-inflammatory diet in RA. Improves fatigue after 2 weeks. Fatigue response dissociated from disease activity response. Open label, but promising. Fatigue remains one of our biggest challenges in RA. Abstr#1699 #ACR21 @RheumNow @ElenaNikiUK https://t.co/tBMqmWAy8m
Richard Conway RichardPAConway ( View Tweet)
Breakthrough COVID-19 in rheum pts: great data @rheum_covid B-cell depleting agents overrepresented, esp in hospitalization in fully vaccinated - but plenty of others Booster (& booster booster) vaccine doses + other mitigation badly needed! @rheum_cat #ACR21 ABSTL04 @RheumNow https://t.co/92Sn3mCwAi
David Liew drdavidliew ( View Tweet)
#Depression is associated with a 3x increased mortality risk in patients with incident #RA. 👉🏼Results from #DANBIO 👉🏼~11000 RA pts, ~1000 starting antidepressants Abs#1659 #ACR21 @RheumNow https://t.co/SsEjmLzacP https://t.co/1GiFE0KLjK

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in PsA. Guselkumab appears superior for joint and skin. Abstr#1773 #ACR21 @RheumNow https://t.co/MTRjXyHoh6
Richard Conway RichardPAConway ( View Tweet)
#ACR21 L04 @rheumcat on #COVID19 in vaxed pts ▶️87 pts in @rheum_covid w/ ifn s/p full vax. 110 partial vax pts ⭐️25% (22/87) full vax pts hospitalized. 45% on BCDT. 8/22 hospitalized had lung disease, 5 no other co-morbidities. 5 deaths (23%). @RheumNow https://t.co/DB8C6jKvuU https://t.co/dxUwjTRxxb

Links:

Eric Dein ericdeinmd ( View Tweet)
You need to visit this nonprofit on the #ACR21 website and also their website https://t.co/8SrCHZUrk0 to help patients & doctors navigate getting the meds pts need. There are resources explaining step therapy and how to navigate access restrictions for patients. @rheumnow

Links:

TheDaoIndex KDAO2011 ( View Tweet)

No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i ⭐️Age, duration of disease, physician global were main differences in TNFi and IL-17i vs. cDMARD ⭐️no specific clustering noted Abs#1782 #ACR21 @RheumNow https://t.co/AH33ZjHUa1 https://t.co/Gb2zKMBUqo

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Dr Kwok on isolated axial disease in PsA. Seen in 2% of cohort. Significantly more likely to be HLA-B27 positive. Lower HAQ score. No obvious predictors of future development of peripheral disease. Abstr#1775 #ACR21 @RheumNow https://t.co/SqpaLjCrmm
Richard Conway RichardPAConway ( View Tweet)
×